- Home
- AIRS vs ANNX Comparison
AIRS vs ANNX Comparison
Compare AIRS & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- ANNX
- Stock Information
- Founded
- AIRS 2012
- ANNX 2011
- Country
- AIRS United States
- ANNX United States
- Employees
- AIRS N/A
- ANNX N/A
- Industry
- AIRS Medical/Nursing Services
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- ANNX Health Care
- Exchange
- AIRS Nasdaq
- ANNX Nasdaq
- Market Cap
- AIRS 333.7M
- ANNX 362.4M
- IPO Year
- AIRS 2021
- ANNX 2020
- Fundamental
- Price
- AIRS $3.31
- ANNX $1.77
- Analyst Decision
- AIRS Hold
- ANNX Strong Buy
- Analyst Count
- AIRS 3
- ANNX 5
- Target Price
- AIRS $3.75
- ANNX $18.67
- AVG Volume (30 Days)
- AIRS 554.5K
- ANNX 1.6M
- Earning Date
- AIRS 05-02-2025
- ANNX 05-12-2025
- Dividend Yield
- AIRS N/A
- ANNX N/A
- EPS Growth
- AIRS N/A
- ANNX N/A
- EPS
- AIRS N/A
- ANNX N/A
- Revenue
- AIRS $172,101,000.00
- ANNX N/A
- Revenue This Year
- AIRS N/A
- ANNX N/A
- Revenue Next Year
- AIRS $5.63
- ANNX N/A
- P/E Ratio
- AIRS N/A
- ANNX N/A
- Revenue Growth
- AIRS N/A
- ANNX N/A
- 52 Week Low
- AIRS $1.53
- ANNX $1.29
- 52 Week High
- AIRS $9.20
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- AIRS 66.45
- ANNX 47.14
- Support Level
- AIRS $2.02
- ANNX $1.60
- Resistance Level
- AIRS $3.12
- ANNX $2.01
- Average True Range (ATR)
- AIRS 0.38
- ANNX 0.13
- MACD
- AIRS 0.17
- ANNX 0.02
- Stochastic Oscillator
- AIRS 97.01
- ANNX 41.46
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.